
How Children Are Exposed To Brain-Harming Chemicals From Mattresses
Babies and young children may breathe and absorb phthalates, flame retardants, and other harmful ... More chemicals from their mattresses while they sleep, according to recent research from the University of Toronto.
Every parent wants their child to sleep safely and soundly. Yet, recent research led by the University of Toronto and co-authored by the Green Science Policy Institute has uncovered a disturbing reality: the very mattresses our babies and young children sleep on may be exposing them to a cocktail of harmful chemicals, including phthalates and flame retardants, night after night.
The first study detected concerning levels of more than two dozen phthalates, flame retardants, and UV-filters in the air of young children's bedrooms, with the highest levels lurking around the beds. A companion study testing 16 newly purchased children's mattresses confirmed that they are likely the major source of these chemicals in children's sleeping environments. When the researchers simulated a child's body temperature and weight on the mattresses, chemical emissions surged.
The phthalates and organophosphate ester flame retardants measured in this study are hormone disruptors and linked to neurological harms, including learning disorders, reduced IQ scores, behavioral problems, and impaired memory. Some are also linked to childhood asthma and cancer. Several UV-filters are hormone disruptors.
Young children are not just 'little adults.' Their developing bodies and brains, higher breathing rates, and hand-to-mouth behaviors make them especially susceptible to the harms of these chemicals. Babies can spend up to 18 hours a day sleeping, meaning their contact with mattresses is prolonged and intimate. Their skin is more permeable, and their surface area relative to body weight is three times that of adults, further increasing their risk. Critically, once a child's brain development is disrupted, the consequences can be permanent and lifelong.
The mattresses were purchased in Canada, but most contained materials originating from other countries including the U.S. and Mexico. Because of integrated mattress markets and supply chains, the results are likely to apply to mattresses purchased throughout North America. The high levels of flame retardants in most of the mattresses tested were therefore puzzling, given these chemicals are not necessary to pass neither Canadian nor U.S. mattress flammability standards. Both countries' updated regulations allow mattresses to pass safety tests without the use of added flame retardants. Flame retardants are linked to neurological, reproductive, and hormonal harm as well as cancer, and also have no proven fire-safety benefit as used in mattresses.
It was unclear whether the chemicals were intentionally added or present due to supply chain contamination. Several mattresses had chemicals that are banned or restricted in Canada, suggesting that manufacturers are not currently testing children's mattresses for these chemicals and other unnecessary chemicals before putting them on the market.
While the burden should not fall on parents to ensure chemical safety of mattresses, there are immediate steps families can take to reduce exposure:
· Declutter the sleeping area: Limit the number of pillows, blankets, and toys, as these can also harbor or emit chemicals.
· Wash bedding frequently: Bedding and pajamas act as a barrier between your child and the mattress. Regular washing helps remove any chemicals that may accumulate.
· Opt for undyed or neutral-colored bedding: Brightly colored fabrics may require additional chemical additives, including UV-filters and plasticizers.
· Advocate for change: Write to manufacturers to demand transparency and safer products, and support policies that restrict harmful chemicals in children's products.
The findings from these studies are a wake-up call for mattress manufacturers and policymakers. Perhaps the most important takeaway is that manufacturers must test their products for these substances and take other precautions to ensure clean supply chains before the products reach the market. For example, the UK's mattress trade association reacted to the study by issuing guidance for its members. The group calls on manufacturers to work with their supply chains to ascertain the presence of certain chemicals in raw materials as it is already possible to produce a specification for mattresses where they are not present.
Governments must also prioritize children's environmental health by implementing more stringent regulations on chemical use in mattresses and other children's products, requiring transparency from manufacturers, and investing in research that further clarifies these connections between environmental exposures and health harms. Every child deserves the right to a safe sleep environment free from invisible chemical hazards that threaten their development, their potential, and ultimately their future.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNN
11 minutes ago
- CNN
Searching for solutions to microplastics in the water
As the UN Oceans Conference gets underway in France, scientists around the world are looking at new ways to tackle the problem of microplastic pollution, Derek Van Dam reports
Yahoo
an hour ago
- Yahoo
Telescope Innovations' Directors Establish Private Debt Instrument to Accelerate Development of Self-Driving Labs
VANCOUVER, British Columbia, June 10, 2025 (GLOBE NEWSWIRE) -- Telescope Innovations Corp. ('Telescope Innovations', 'Telescope', or the 'Company') (CSE: TELI) (OTCQB: TELIF) (FSE:4JU) is a leader in intelligent automation platforms for accelerating chemical process development. The Company announces that it has entered into a secured loan facility with a group of lenders which includes Jason Hein and Henry Dubina, pursuant to which the Company has received a loan (the 'Loan') in the amount of CAD $1,200,000 to support operational activities. The Loan bears interest at a rate of 6.95% per annum and matures on June 1, 2026. Each of Messrs. Hein and Dubina are directors of the Company and are related parties of the Company pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ('MI 61-101'). As a result, the portion of the Loan provided by Messrs. Hein and Dubina, which totals CAD $600,000, constitutes a 'related party transaction'. The Company is relying on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 pursuant to Sections 5.5(a) and 5.7(1)(a) respectively, as neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the Loan exceeds 25.0% of the Company's market capitalization. 'This private credit instrument demonstrates the commitment and continued enthusiasm of our founder, board and executive management to accelerate the development of the Company's Self Driving Laboratory ('SDL') platforms. We are on the verge of introducing our break-through technology platform to address this completely underserved, rapidly growing market opportunity,' commented Henry Dubina, CEO and Chairman of the Board of Directors of Telescope. Dr. Jason Hein, Founder and CTO, said, 'Our SDL pairs robotics with real-time chemistry analytics and machine-learning-guided experimental loops. The system sets up reactions, measures kinetics on the fly, and decides on the next experiment without researcher slowdown — exactly the automation, data connectivity, and AI foundations that are still lacking as global pharma companies race to modernize their labs. We are accelerating our SDL development efforts precisely when most big-pharma labs are budgeting multi-million dollar upgrades. By acting now, we are positioning Telescope at the forefront of this industry shift.' The Company paused the previously announced non-brokered private placement equity financing (February 4th, 2025) due to tariff uncertainty and public market volatility. Currently, private credit offered the optimum flexibility to the Company than traditional commercial credit due to better terms, repayment schedules, covenants, and collateral requirements. As conditions improve, the Company may seek future equity financing as and when the Company needs. About Telescope Innovations Telescope Innovations is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. Our aim is to bring modern chemical technology solutions to meet the most serious challenges in health and sustainability. On behalf of the Board, Telescope Innovations Corp. Henry Dubina, Chief Executive Officer Forward-Looking Information Forward-looking information is based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, and uncertainties that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law. CONTACT: Henry Dubina, Chief Executive Officer E: hdubina@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Medscape
2 hours ago
- Medscape
SLEEP 2025
Narcolepsy an Independent Cardiovascular Disease Risk Factor Narcolepsy is associated with an increased risk for CVD, independent of common comorbid conditions and medications used to treat the disorder, new research showed. Medscape Medical News , Jun 07, 2024 Narcolepsy an Independent Cardiovascular Disease Risk Factor Better Sleep Tied to Less Loneliness Good quality sleep may have a role in driving down rates of loneliness, especially among younger adults. Medscape Medical News , Jun 21, 2024 Better Sleep Tied to Less Loneliness Couples-Based Tx for Sleep Apnea Nurtures Happier Relationships Couples-based therapy called WePAP boosted treatment adherence for sleep apnea, leading to higher relationship satisfaction and lower levels of conflict, a study suggested. Medscape Medical News, xx-Date-Here-xx